Why the study?
Does macrolide therapy reduce mortality in patients with community-acquired pneumonia?
Does macrolide therapy reduce mortality in patients with community-acquired pneumonia?
Macrolides may offer mortality benefits in community-acquired pneumonia, particularly in severe cases with sepsis, potentially due to nonantibiotic pleiotropic effects.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chun et al. (2015) conducted an editorial in Community-acquired pneumonia (CAP). Macrolide therapy vs. Nonmacrolide regimens was evaluated on Mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: